About Us
Gateway to the World
Delivering
Japanese Innovation
to the Global Market
Japanese Innovation
to the Global Market
NANO Holdings serves as a gateway
that brings to light
Japanese-born technologies
whose value has not yet been fully realized,
creates new business value,
and connects them
to global growth.
that brings to light
Japanese-born technologies
whose value has not yet been fully realized,
creates new business value,
and connects them
to global growth.
Team Member
A Team Built for Global Value Creation
NANO Holdings brings together leaders in management, science, and investment to help Japan-born innovation scale globally.
NANO Holdings brings together leaders in management, science, and investment to help Japan-born innovation scale globally.
Management Professionals
Ryutaro Katayama
Board Member, Nano Bridge Investment Co., Ltd.
A management and investment professional with expertise in corporate growth and turnaround
He has managed Japanese companies as well as multiple global firms and has delivered numerous successful results. As Managing Director at the Industrial Revitalization Corporation of Japan, he led what was at the time the largest turnaround project in its history and generated more than half of the organization’s total profit. He has served as outside director and advisor to many turnaround and growth companies and is highly regarded for his expertise. He also participated in the founding of Whiz Partners has been involved in more than 100 M&A transactions, with an extensive network across industries. MBA, Harvard University.
Nobuhiro Todokoro
Board Member, CGO / Board Member, NANO MRNA Co., Ltd. Driving val
Driving value enhancement and carve-out strategy for portfolio companies
He served as Senior Executive Vice President at Nitto Denko, where he led the growth of the display materials business from a small-scale operation to a core business generating hundreds of billions of yen.
Even during industry maturity, he maintained high profitability through technological innovation, structural reform, and collaboration with supply chain partners. He continues to maintain a global network and also has deep knowledge of the pharmaceutical industry as former CEO of the drug discovery CRO Axcelead.
Even during industry maturity, he maintained high profitability through technological innovation, structural reform, and collaboration with supply chain partners. He continues to maintain a global network and also has deep knowledge of the pharmaceutical industry as former CEO of the drug discovery CRO Axcelead.
Yoshihisa Kaneko
Chief Marketing Officer
A corporate growth professional with deep expertise in capital strategy and management
He spent many years in investment banking at Daiwa Securities, working in corporate finance and institutional business divisions, and later served as Senior Managing Director overseeing corporate and IPO divisions. He subsequently served as President of Daiwa Fund Consulting and has extensive experience in the asset management industry. He also has broad knowledge of corporate functions including PR, IR, general affairs, executive support, and corporate administration.
Ichiro Nakatomi, Ph.D.
Board Member, CNO
Supporting the Company’s growth strategy through extensive experience and global networks
He is a founder with IPO experience on both NASDAQ and the Tokyo Mothers market, and a leader who combines both investor and management perspectives in strategic decision-making. Leveraging strong relationships with top pharmaceutical industry leaders, he contributes to the business growth and value enhancement of the Company and its portfolio companies. He also served as President of the Licensing Executives Society International (LESI) and has extensive experience in global intellectual property networks and business development.
Rocky H. Kato
Nano Holdings US, LLC President
Driving growth and innovation with over 30 years of global experience
Rocky leads the expansion of U.S. operations at Nano Holdings US and plays a key role in accelerating the growth of portfolio companies. He is a seasoned executive with more than 30 years of experience across healthcare, technology, and environmental industries. At Hitachi, Ltd., he led global new business development and venture investments from London, San Francisco, and Tokyo, contributing to significant profit growth for over 15 years. He has also served as CEO and COO of several venture companies, successfully leading them through IPOs and M&A transactions. Earlier in his career, he was active internationally as a professional race car driver, a background that reflects the precision, discipline, and drive he brings to business leadership today.
Chieko Tsuchiya
Chief Corporate Communication Officer
Bridging Research, Investment and Capital Markets to Maximize Corporate Value
After engaging in research on DDS-based anticancer drugs and gaining firsthand experience in the drug discovery field, she transitioned into investor relations, where she communicates corporate value to the capital markets. She has developed strong expertise in engaging with investors and the financial community. Leveraging a background spanning research, business, and finance, she supports IR strategy and helps enhance corporate value by effectively conveying growth strategies and development initiatives to the capital markets.
Legendary Scientists
Neil Gibson, Ph.D.
Nano Holdings US, LLC Chairman
A legendary leader in oncology drug development with four blockbuster therapies
A legendary figure in the healthcare industry who has led pharmaceutical research and development for more than 30 years, primarily in the field of oncology. He contributed to the research, development, and commercialization of four blockbuster drugs, including temozolomide, sorafenib, erlotinib, and crizotinib, and has held executive positions such as CEO and CSO at multiple companies, including Pfizer. More recently, he founded four venture companies and has driven the development of innovative medicines addressing unmet medical needs. He has extensive experience in fundraising, M&A, IPOs, and strategic growth initiatives, and is a trusted partner for investors.
Michael Houston, Ph.D.
Advisor
A biotechnology innovator with outstanding achievements in drug discovery and CDMO
Dr. Houston is a scientist with a distinguished track record in advanced therapeutic modalities, including peptides, proteins, siRNA, and mRNA. He has led the development of innovative APIs and delivery formulations from early concept through research and clinical development. After serving in a leadership role at TriLink Biotechnologies, he founded Artis BioSolutions and currently leads the company as Chief Scientific Officer. He is recognized as a scientific leader who builds and directs multidisciplinary expert teams and drives the future of therapeutic development and manufacturing.
Shiro Akinaga, Ph.D.
Board Member, CTO / Representative Director, President, NANO MRNA Co., Ltd.
A pioneer in next-generation drug discovery with experience across three modalities
He served as Executive Officer / Fellow at Kyowa Hakko Kirin and later moved to the bio-venture industry. He is one of the few scientist-executives with achievements across three generations of drug discovery modalities, including antibody therapeutics (mogamulizumab), nucleic acid therapeutics (siRNA / ASO), and mRNA medicines. He leads the evaluation of development compounds and modalities for next-generation medicine and drives the formulation of commercialization strategies.
Kazunori Kataoka, Ph.D.
Founder
A Global Authority in Nanotechnology Enhancing Investment Value Through Science
A world-renowned authority in nanotechnology who provides deep scientific insight in evaluating portfolio technologies. He supports the enhancement of value in acquired companies and investment targets. Leveraging extensive experience in academia–industry collaboration and global networks, he contributes to driving business growth and the creation of next-generation industries.
Teruo Okano, Ph.D.
Founder
A Global Pioneer Bridging Innovation in Regenerative Medicine
A pioneer in regenerative medicine who established cell sheet engineering and has led global research toward its clinical application. He provides deep scientific insight in evaluating portfolio technologies and supports enhancing the value of acquisition pipelines. Leveraging an extensive international research network and experience in academia–industry collaboration, he contributes to the creation of next-generation medical innovations.
Yasunori Yamaguchi, Ph.D.
Chief Business Development Officer
Driving value creation through global business development and strategic alliances
At Kyowa Kirin, he held roles in research, strategy, and business development, leading international alliances and business strategy in antibody therapeutics and cell therapy. He later served as CEO of a U.S. subsidiary, overseeing global operations, and as President of IP Gaia, where he built strong networks with academia and pharmaceutical companies and established business models from early discovery to licensing. At NANO Holdings, he contributes to building and promoting a value-creation platform through business development and alliances.
Daisuke Nakashima
Board Member, NANO MRNA Co., Ltd.
A global drug development strategist with experience across all modalities
He has nearly 30 years of experience at a Japanese pharmaceutical company as a specialist in pharmacokinetics and clinical pharmacology.He has worked across all major modalities, including small molecules, protein therapeutics, antibody drugs, and nucleic acid / mRNA medicines. Most recently, he successfully led the establishment of an overseas subsidiary in Australia and the initiation of first-in-human trials, contributing to global business development and acceleration of drug development.
Norihiko Shiraishi, Ph.D.
Board Member, NANO MRNA Co., Ltd.
Integrating science and strategy to lead next-generation drug development
He has more than 20 years of experience at a Japanese pharmaceutical company in drug discovery research, global clinical development, corporate planning, and new business development. He evaluates cutting-edge products and technologies from both scientific and strategic perspectives, while continuing to lead research organizations and drive the creation of new pipelines in mRNA drug discovery.
Kenichiro Naito, Ph.D.
Fellow, NANO MRNA Co., Ltd.
An expert in identifying value across therapeutic areas and development stages
He spent approximately 30 years in drug discovery at a pharmaceutical company with more than 40 years of history, contributing to the globalization of research and development.
He has overseen entire R&D portfolios and developed strategies to maximize the value of individual projects. Through strong relationships with overseas sites, he has optimized project execution and accelerated development by allocating functions to the most suitable global locations.
He has overseen entire R&D portfolios and developed strategies to maximize the value of individual projects. Through strong relationships with overseas sites, he has optimized project execution and accelerated development by allocating functions to the most suitable global locations.
Investment Professionals
Atsushi Matsumura
Representative Director Chairman, President & CEO / Board Member, NANO MRNA Co., Ltd.
An investment and management expert driving corporate growth through strategic investment
After working in corporate finance at Nomura Securities in Japan and Europe, he founded Whiz Partners and has served as a fund manager whose past funds achieved world-leading performance in the growth sector in the 2000s. Through his proprietary investment approach and hands-on strategy, he has enhanced the value of portfolio companies. He has outstanding fund formation capabilities and maintains strong networks with investors and corporate executives both in Japan and overseas.
Satoru Iino
Board Member, CIO / Representative Director, President, Nano Bridge Investment Co., Ltd.
A fund manager with extensive experience in Japan and overseas
He has over 25 years of experience in venture capital (VC) and private equity (PE), with a strong track record of successful investments in numerous growth companies. His experience includes international technology alliances at Hitachi, early-stage support for bio ventures at CSK Venture Capital, and value enhancement of listed companies at Whiz Partners. He possesses both a broad investment network and a strong track record in Japan and overseas.
Makoto Kosaka
Senior Supervisor / Corporate Auditor, Nano Bridge Investment Co., Ltd.
Contributing to Effective Communication Between Venture Companies and Stakeholders
With 25 years of experience in internal control and risk management at financial institutions, audit firms, and consulting companies, he has provided both practical and advisory expertise in governance and risk management. He later served as Director and CFO/COO of a technology venture and as Head of Internal Audit at a carve-out company, where he built governance and internal control frameworks and supported IPO review processes. He contributes to strengthening governance and facilitating effective communication with stakeholders.
CIIA (Certified International Investment Analyst), CIA (Certified Internal Auditor), AIP (Advanced IPO Professional).
CIIA (Certified International Investment Analyst), CIA (Certified Internal Auditor), AIP (Advanced IPO Professional).
Hironobu Yamanaka
Strategic Investment Unit Officer
Leading Global Investment Management and Deal Execution
He oversees investment transaction management and the overall deal process. With more than 20 years of global experience in the healthcare and biotechnology sectors, he manages the execution of M&A and carve-out transactions. At Danaher Corporation, he drove business development initiatives, and at Leica Microsystems’ headquarters in Switzerland, he led the planning and global launch of medical devices across the U.S., Europe, and Asia, while also overseeing the acquisition and integration of U.S. venture companies. He began his career at Japan’s Ministry of Economy, Trade and Industry (METI), where he was involved in policy development.
Company
Profile
Profile
| Corporate Name | Nano Holdings, Inc. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Exchange Listing | Tokyo Stock Exchange Growth Market (Code: 4571) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Location |
Head office
Google maps
Atago Green Hills MORI Tower 26F 2-5-1 Atago, Minato-ku, Tokyo TEL：+81 (0)3-6432-0020 FAX：+81 (0)3-6432-4794 
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Establishment | June 14, 1996 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Board Member |
Representative Director, Chairman, President & CEO
Atsushi Matsumura
Board Member, Chief Investment Officer (CIO)
Satoru Iino
Board Member, Chief Growth Officer (CGO)
Nobuhiro Todokoro
Board Member, Chief Financial Officer(CFO) Chief Administrative Officer (CAO) Chief Compliance officer（CCO）
Takashi Matsuo
Board Member, Chief Technology Officer (CTO)
Shiro Akinaga
Board Member, Chief Network Officer (CNO)
Ichiro Nakatomi
Board Member
Hajime Kurozu
Board Member
Takashi Ejiri
Audit & Supervisory Board Member
Seiichiro Wada
Audit & Supervisory Board Member
Niro Sakamoto
Audit & Supervisory Board Member
Takuma Shimizu
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Scopes of Business | Investment business | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Subsidiary Company |
Nano Bridge Investment Co., Ltd. Nano Holdings US, LLC NANO MRNA Co., Ltd. NANO MEDIA, Inc. |
